Therapeutic management of patients with lung cancer during the COVID-19 pandemic
Keywords:
Lung Neoplasm, Coronavirus Infections, Cancer Care Facilities, Oncology Service, Hospital, COVID-19Abstract
Introduction: On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. Lung cancer patients are more susceptible to coronavirus infection, due to the state of immunosuppression caused by both cancer and treatments, such as chemotherapy or surgery.
Objective: to characterize the therapeutic management of patients with lung cancer during the COVID-19 pandemic
Method: a search for information was performed by combining terms in the PubMed, SciELO, LILACS, Cochrane Library and Web of Science databases; selecting 30 of these.
Development: the successful management of lung cancer requires frequent visits to the hospital and admission for research, radiotherapy, chemotherapy, among others. Over the course of many weeks, this added to the immunosuppression and the poor functional and structural condition of the lungs, poses a great risk of SARS-CoV-2 infection. The treatment of lung cancer presents variations in the case of COVID-19 infection, limiting itself in some of the therapeutic options such as surgery and adjuvant therapy, which in some cases must be postponed.
Conclusions: cancer patients may be more susceptible to infection. Treatment of lung neoplasia should be carried out with a series of adjustments according to the status of the local epidemic to reduce the risk of tumor progression and COVID-19 infection.
Downloads
References
2. Flick H, Arns BM, Bolitschek J, Bucher B, Cima K, Gingrich E, et al. Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic. Wien Klin Wochenschr [Internet]. 2020 [citado 10/06/2020]; 47(4):[aprox 7 p]. Disponible en: https://doi.org/10.1007/s00508-020-01691-0
3. Ismael J, Losco F, Quildrian S, Sanchez P, Pincemin I, Lastiri J, et al. Multidisciplinary approach to COVID-19 and cancer: consensus from scientific societies in Argentina. ecancer [Internet]. 2020 [citado 10/06/2020]; 14:1044. Disponible en: https://doi.org/10.3332/ecancer.2020.1044
4. Chen H, Wu X, Wang W, Wang Q. When cancer encounters COVID-19 in China: what have we suffered, experienced and learned. JJCO. [Internet]. 2020 [citado 10/06/2020]; 1–7. Disponible en: http://ncbi.nlm.nih.gov/pmc/articles/PMC7239118/pdf/hyaa077.pdF
5. Opening remarks at the media briefing on covid-19. Organización Mundial de la Salud [Internet]. Suecia: OMS; 2020 [actualizado 11 de marzo 2020; citado 18 de junio de 2020]. Disponible en: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
6. García-Navarro CA, Marrades Sicart R, Molins López R. Tumores broncopulmonares. En: C. Rozman, A. Agustí et al, editores. Medicina Interna. Vol 2. 17ma edición. España: Elsevier; 2012. p.722-734.
7. Horn L, Pao W, David H. Johnson. Neoplasia de pulmón. En: Barnes PJ. Longo DL, Fauci AS, et al, editores. Harrison principios de medicina interna. Vol 1. 18ª ed. México: McGraw‐Hill; 2012. p. 737‐753.
8. Noor Husain A. Pulmón. En: Vinay Kumar, Abul K.Abbas, Jon C.Aster, et al, editores. Robins Patología Humana. 9na ed. España: Elsevier; 2012. p. 505-523.
9. Shankar A, Saini D, Bhandari R, Bharati SJ, Kumar S, Yadav G, et al. Lung cancer management challenges amidst COVID-19 pandemic: hope lives here. Lung Cancer Manag. [Internet]. 2020 [citado 10/06/2020]; 10:2217. Disponible en: http://ncbi.nlm.nih.gov/pmc/articles/PMC7202360/PDF/LMT- 2020 - 0012.pdf
10. Dingemans AM, Soo RA, Jazieh AR, Rice SJ, Kim YT. Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. J Thorac Oncology. [Internet]. 2020 [citado 10/06/2020]; 15: 1119-1136. Disponible en: https://doi.org/10.1016/j.jtho.2020.05.001
11. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: 2020 Guidance for Lung Cancer in COVID-19 15 implications for COVID-19. Eur Respir J [Internet]. 2020 [citado 10/06/2020]; 55(5):2000688. Disponible en: https://doi.org/10.1183/13993003.00688-2020
12. Guan WJ, Ni ZY, Hu Y, Liang C, Ou J, He L, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med [Internet]. 2020 [citado 10/06/2020]; 382:1708–1720. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa2002032
13. Chen N, Zhou M, Dong X, Qu J, Gong F, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. [Internet]. 2020 [citado 10/06/2020]; 395:507–513. Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2820%2930211-7/fulltext
14. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China [e-pub ahead of print]. Allergy [Internet]. 2020 [citado 27/06/2020]; 75(7):1730-1741. Disponible en: https://doi.org/10.1111/all.14238
15. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo controlled, multicenter trial. The Lancet [Internet]. 2020 [citado 20/06/2020]; 395(10236):1569-1578. Disponible en: https://doi.org/10.1016/S0140-6736(20)31022-9
16. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncol [Internet]. 2020 [citado 10/06/2020]; 21(3): 335-337. Disponible en: http://dx.doi.org/10.1016/S1470-2045(20)30096-6
17. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respir Med [Internet]. 2020 [citado 10/06/2020]; 8 (4): 420-422. Disponible en: https://doi.org/10.1016/S2213-2600(20)30076-X
18. Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for patients with cáncer. Lancet Onco. [Internet]. 2020 [citado 23/06/2020]; 21:2020. Disponible en: https://doi.org/10.1016/S1470-2045(20)30150-9
19. Salazar MC, Rosen JE, Wang Z, Arnold BN, Thomas DC, Herbst RS, et al. Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. JAMA Oncol [Internet]. 2017 [citado 23/06/2020]; 3 (5): 610–19. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824207/
20. Yang L, Xu HY, Wang Y. Diagnostic and therapeutic strategies of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19). Zhonghua Zhong Liu Za Zhi [Internet]. 2020 [citado 23/06/2020]; 42: e006. Disponible en: https://europepmc.org/article/med/32118394
21. Arrieta O, Cardona AF, Lara L, Heredia D, Barrón F, Zatarain-Barrón ZL, et al. Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID‐19 pandemic: The THOCOoP cooperative group. Crit Rev Oncol/Hematology. [Internet]. 2020 [citado 10/06/2020]; 153: 103033. Disponible en: https://doi.org/10.1016/j.critrevonc.2020.103033
22. Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C. COVID-19 in patients with lung cáncer. Ann Oncol. [Internet]. 2020 [citado 10/06/2020]; S0923-7534 (20): 39894-X. Disponible en: https://doi.org/10.1016/j.annonc.2020.06.007
23. Guckenberger M, Belka C, Bezjak A, Bradley J, Daly ME, DeRuysscher D, et al. Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiotherapy Oncol. [Internet]. 2020 [citado 23/06/2020]; 146: 223-229. Disponible en: https://doi.org/10.1016/j.radonc.2020.04.001
24. Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Crit Rev Oncol/Hematology. [Internet]. 2020 [citado 23/06/2020]; 150: 102972. Disponible en: https://doi.org/10.1016/j.critrevonc.2020.102972
25.Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, et al. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic. J Am Coll Radiol. [Internet]. 2020 [citado 23/06/2020]; 17(7):845-854. Disponible en: https://doi.org/10.1016/j.jacr.2020.04.024
26.Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol [Internet]. 2020 [citado 23/06/2020]; 21:2020. Disponible en: https://doi.org/10.1016/S1470-2045(20)30309-0
27.Xu Y, Liu H, Hu K, Wang M. Clinical recommendations on lung cancer management during the COVID-19 pandemic. Thoracic Cancer. [Internet]. 2020 [citado 23/06/2020]; 11: 2067–2074. Disponible en: http://ncbi.nlm.nih.gov/pmc/articles/PMC7283707/pdf/TCA-9999-na.pdf
28. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology [Internet]. 2020 [citado 23/06/2020]; 296(2): [aprox 12 pag]. Disponible en: http://doi:10.1148/radiol.2020200343
29. Masjedi H, Omidi R, Zamani H, Perota G, Zare MH. Radiation dose and risk of exposure-induced death associated with common computed tomography procedures in Yazd Province. Eur J Radiol [Internet]. 2020 [citado 23/06/2020]; 126:108932. Disponible en: http://dx.doi.org/10.1016/j.ejrad.2020.108932
30. National Lung Screening Trial Research T. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med [Internet]. 2020 [citado 23/06/2020]; 365:395–409. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21714641/